Michael Schümann - Concepedia

Author

Michael Schümann

Charité - Universitätsmedizin Berlin ORCID

Also Known As

Francesca Ronchi, J. Suarez de Lezo Herreros de Tejada, M Schumann, M Schümann, M. Schumann, M., Schumann, MICHAEL SCHÜMANN, Marja-Leena Lähdeaho, Martin L. Schumann, Michael Schumann

349

Publications

9.6K

Citations

H-Index

145

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Humboldt-Universität zu Berlin Freie Universität Berlin Leibniz-Forschungsinstitut für Molekulare Pharmakologie Berlin Institute of Health at Charité - Universitätsmedizin Berlin

About

Michael Schümann is an author at Charité - Universitätsmedizin Berlin specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	34	2.7K
2	Business	3	3	186
3	Education	3	3	186
4	Engineering	2	2	251
5	Management	2	2	135

Michael Schümann

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Peptide Helicity and Membrane Surface Charge Modulate the Balance of Electrostatic and Hydrophobic Interactions with Lipid Bilayers and Biological Membranes Margitta Dathe, Michael Schümann, Torsten Wieprecht, Biochemistry Membrane StructureProteinlipid InteractionBiochemistryProtein FoldingNatural Sciences	1996	405
Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD Donata Lissner, Michael Schümann, Arvind Batra, Inflammatory Bowel Diseases	2015	359
Processing of Genome 5′ Termini as a Strategy of Negative-Strand RNA Viruses to Avoid RIG-I-Dependent Interferon Induction Matthias Habjan, Ida Andersson, Jonas Klingström, PLoS ONE Viral ReplicationViral Polymerase MechanismGeneticsImmunologyViral Pathogenesis	2008	318
IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin–directed vascular barrier disruption Victoria Langer, Eugenia Vivi, Daniela Regensburger, Journal of Clinical Investigation	2019	237
Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa—A first in vivo study in human patients Carsten Schmidt, Christian Lautenschlaeger, Eva-Maria Collnot, Journal of Controlled Release NanoparticlesNanomedicineVivo StudyNanotherapeuticsEngineering	2012	225
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease Detlef Schuppan, Markku Mäki, Knut E. A. Lundin, New England Journal of Medicine	2021	206
Synthesis of ‘difficult’ peptide sequences: application of a depsipeptide technique to the Jung–Redemann 10- and 26-mers and the amyloid peptide Aβ(1–42) Louis A. Carpino, Eberhard Krause, Calin Dan Sferdean, Tetrahedron Letters BiochemistryDepsipeptide TechniqueProtein FoldingPeptide EngineeringAmyloid Peptide Aβ	2004	183
Marburg Virus Evades Interferon Responses by a Mechanism Distinct from Ebola Virus Charalampos Valmas, Melanie N. Grosch, Michael Schümann, PLoS Pathogens Mechanism DistinctViral PathogenesisImmunologyVirus TransmissionMarburg Viruses	2010	179
Ebola Virus VP35 Antagonizes PKR Activity through Its C-Terminal Interferon Inhibitory Domain Michael Schümann, Thorsten Gantke, Elke Mühlberger Journal of Virology Molecular VirologyPkr InhibitionPathogenesisViral PathogenesisImmunology	2009	138
Mechanisms of epithelial translocation of the α<sub>2</sub>-gliadin-33mer in coeliac sprue Michael Schümann, J Richter, I Wedell, Gut	2008	130

Page 1